Amolyt Pharma

Amolyt Pharma, Inc. develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Its goal is to become a leading company in the rare disease field, operating in Europe and the United States, and supporting global product development. Amolyt Pharma, Inc. is building an innovative and balanced portfolio to address significant unmet medical needs. Its first two assets are AZP-3601, a parathyroid hormone analog for hypoparathyroidism, and AZP-3404, a peptide that leverages IGFBP2 biology to treat severe insulin resistance syndrome.